Entero Healthcare Solutions Limited · NSE:ENTERO
Entero Healthcare Solutions — Q1 FY26 Earnings Presentation
36 slides from Entero Healthcare Solutions's earnings presentation, August 2025
Slide 1: Entero Healthcare Solutions Limited Investor Presentation – August 2025
Everything in Pharma… Everywhere in India… Entero Healthcare Solutions Limited Investor Presentation – August 2025
Slide 2: Safe Harbour
Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by Entero Healthcare Solutions Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe
Slide 3: Q1 FY26 Financial Highlights
Q1 FY26 Financial Highlights
Slide 4: Management Commentary
Management Commentary We have started the new financial year on a strong note, with Q1 revenue growing 28% YoY (as against the IPM growth of 9%) to ₹1,404 crore and PAT rising 47% to ₹30.2 crore. We continue to deliver on the vast consolidation opportunity in an extremely fragmented healthcare suppl
Slide 5: Operational Highlights
Operational Highlights Outperforming Customers Relationship with Market Growth SKU’s Handled (Retailers) healthcare product (Q1FY26) manufacturers Entero: 28% › Q1FY26: 71,000+ › Q1FY26: 74,700+ › Q1FY26: 2,600+ IPM: 9% › Q1FY25: 60,300+ › Q1FY25: 64,100+ › Q1FY25: 2,000+ Customers Districts Covered
Slide 6: Growing faster than Industry… Gaining Market Share
Growing faster than Industry… Gaining Market Share High base effect due to COVID-19 IPM Entero Organic Growth Entero Consolidated Growth 65% 53% 40% 41% 38% 37% 35% 35% 32% 31% 31% 29% 28% 26% 27% 24% 21% 22% 19% 19% 19% 20% 16% 16% 17% 15% 15% 14% 15%* 18% 17% 17% 11% 16% 15% 11%* 10% 9% 10% 9% 9%
Slide 7: Consolidated Financial Highlights
Consolidated Financial Highlights Revenue (Rs. Cr) Gross Profit (Rs. Cr) & Margin (%) +28% +40% 1,404 140 1,097 100 9.9% 9.1% Q1FY25 Q1FY26 Q1FY25 Q1FY26 EBITDA (Rs. Cr) & Margin (%) PAT (Rs. Cr) +66% +47% 50 30 21 30 3.6% 2.8% 2.2% 1.9% Q1FY25 Q1FY26 Q1FY25 Q1FY26 7
Slide 8: Key Balance Sheet Highlights
Key Balance Sheet Highlights Net Operating Working Capital (Days) RoCE (%) RoE (%) 71 11.6% 11.5% 9.5% 66 66 9.0% 8.5% 5.7% Q1 FY25 Q4 FY25 Q1 FY26 Q1 FY25 Q4 FY25 Q1 FY26 Q1 FY25 Q4 FY25 Q1 FY26 RoCE: EBIT / Average Capital Employed (Capital Employed = Tangible Networth + Borrowings + Deferred Tax
Slide 9: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement Particulars (Rs. Cr) Q1FY26 Q1FY25 YoY% Revenue 1,403.8 1,097.0 28% Cost of Goods Sold 1,264.2 997.1 Gross Profit 139.6 100.0 40% Gross Margin (%) 9.9% 9.1% 83 bps Employee Expenses 56.7 42.8 ESOP Expenses 0.9 0.7 Other Expenses 31.9 26.2 EBITDA 50.1 30.2 66% EBI
Slide 10: Utilization of IPO Proceeds
Utilization of IPO Proceeds Amount to be funded Particulars (Rs. Cr) Utilized till date Unutilized from Net Proceeds Repayment/prepayment, in full or part, of certain borrowings availed of by our 142.5 142.5 - Company Funding of long-term working capital requirements of the Company and its 480.0 428
Slide 11: Award of "Excellence in Healthcare Supply Chain and Logistics- 2024"
Award of "Excellence in Healthcare Supply Chain and Logistics- 2024" We are extremely thrilled to announce that Entero Healthcare Solutions has been honored with the Excellence in Healthcare Supply Chain & Logistics 2024 award at the ET Healthcare Awards this year! This prestigious recognition under
Slide 12: About Us
About Us
Slide 13: We are a Healthcare Supply Chain Solutions Specialist
We are a Healthcare Supply Chain Solutions Specialist Amongst the top three healthcare products distributors in India in terms of revenue Our Warehouses Fastest scale-up of operations among healthcare products distributors in India with track record of 50* acquisitions Pan-India presence through our
Slide 14: Entero at a Glance
Entero at a Glance Geographical Reach of Distribution Network 71,000+ 2,500+ 2,600+ Customers Retail Pharmacies Hospital Supply relationships with catered to customers healthcare product manufacturers AMRITSAR PANCHKULA DEHRADUN KARNAL DELHI GHAZIABAD GURGAON FARIDABAD JAIPUR GORAKHPUR AYODHYA BASTI
Slide 15: Building a Highly Scalable Business Model
Building a Highly Scalable Business Model Consolidated Revenue (Rs. Cr) Customers (Retailers) Customers (Hospitals) FY23 81,400+ FY23 3,400+ 5,096 FY24 86,300+ FY24 3,500+ FY25 95,300+ FY25 3,600+ Relationship with healthcare +30% CAGR 3,922 SKU’s Handled product manufacturers 3,300 FY23 64,500+ FY2
Slide 16: Strong Board backed by a Healthcare-Focused Investors
Strong Board backed by a Healthcare-Focused Investors Prabhat Agrawal Sujesh Vasudevan Rajesh Shashikant Dalal Sandhya Gadkari Sharma Promoter, Managing Director and Chairperson and Non-Executive Non-Executive Independent Non-Executive Independent CEO Independent Director Director Director Prem Seth
Slide 17: Leadership Team
Leadership Team Prabhat Agrawal Prem Sethi Balakrishnan Natesan Kaushik Promoter, Managing Director and CEO Promoter, Whole-time Director and COO Group Chief Financial Officer ◼ Previous experience as CEO with Alkem Laboratories, ◼ Previous experience as Director – Offering Development and ◼ Previou
Slide 18: Leadership Team
Leadership Team Sanu Kapoor Sambit Mohanty Abhitesh Kumar Vice President - General Counsel, Company President - Institutional Business President - Retail Business & New Initiatives Secretary and Compliance Officer • Associate member of the Institute of Company Secretaries • Bachelor’s of science fro
Slide 19: Market Opportunity
Market Opportunity
Slide 20: Pharmaceutical Supply Chain in India is Highly Fragmented
Pharmaceutical Supply Chain in India is Highly Fragmented Player in Value Chain Typical Functions and Role No. of Players Typical Margin range Pharmaceutical and Healthcare Companies ~3,000 Products Manufacturer ▪ Manufacturing units supplying finished products 40 – 60% Man. Units 10,500 ▪ Marketer
Slide 21: Key Challenges in the Pharmaceutical Supply Chain
Key Challenges in the Pharmaceutical Supply Chain Pharmaceutical and Healthcare Products Manufacturer / High expiries due to multiple Complexity of dealing with Limited or no secondary sales No direct reach to retailers, Inadequate storage stock points and no data Marketer multiple sub-scale distrib
Slide 22: Healthcare Products Distribution Market Overview
Healthcare Products Distribution Market Overview Large and Growing Target Addressable Market… …Led by Increasing Share of Large / National Distributors Share of the total distributor sales for Large / National pharmaceutical distributors 20-30% CAGR $33.2bn 10-11% 25-30% 8-10% Target Addressable Mar
Slide 23: Key Strengths
Key Strengths
Slide 24: Key Strengths
Key Strengths We Operate in the Large and Highly Fragmented Indian Healthcare Products Distribution Market and Expect to Benefit from Market Consolidation We are One of India’s Largest and Fastest Growing Healthcare Products Distribution Platforms Track Record of Inorganic Expansion and Integration
Slide 25: Highly Fragmented Market… to Accelerate Consolidation
Highly Fragmented Market… to Accelerate Consolidation US China India(1) Germany Top 3: 90 – 95% Top 4: 40 – 45% Top 3: 8 – 10% Top 5: 95 – 97% Share of Large Players in the Pharma Distribution Top 3 Top 4 Top 3 Top 5 / All Share of Top x 2020 90 – 95% 40 – 45% 8 – 10% 95 – 97% in Total Pharma Distri
Slide 26: One of India’s Largest & Fastest Growing Healthcare Supply Chain Company
One of India’s Largest & Fastest Growing Healthcare Supply Chain Company Geographical Reach of Distribution Network Distribution Presence 19 States 45/469 Cities/Districts AMRITSAR Customer Network PANCHKULA DEHRADUN KARNAL GHAZIABAD DELHI Retail GURGAON FARIDABAD Hospital JAIPUR GORAKHPUR AYODHYA B
Slide 27: Successful track record of Acquisitions and Integration
Successful track record of Acquisitions and Integration Track Record of Growth of Acquired Companies Acquisition Strategy Distributor Name Date of Acquisition Location FY21-23 Growth R.S.M Pharma 14-Aug-2018 Bengaluru ~69% › Take advantage of market consolidation opportunities available Getwell Medi
Slide 28: Differentiated Business Model
Differentiated Business Model Offers both demand generation and demand fulfilment capabilities to healthcare brands and product manufacturers Demand Generation via Integrated Demand Fulfilment via end-to-end healthcare products distribution solutions Commercial Solutions Deploy Medical Representativ
Slide 29: Proprietary Technology Platform
Proprietary Technology Platform with Integrated Business Intelligence Tools and Solutions Technology-Focused Approach Anchored on Our Proprietary Integrated Tech …To Grow our Operations and Bring Efficiencies in the Healthcare Platforms and Business Intelligence Tools… Products Distribution Ecosyste
Slide 30: Key Growth Drivers
Key Growth Drivers Benefit from healthcare products distribution market consolidation with strategic acquisitions Strengthen market position through increases in customer base, wallet share and geographic penetration Pursue comprehensive marketing and distribution collaborations with healthcare prod
Slide 31: Historical Financials
Historical Financials
Slide 32: Historical Financial Highlights
Historical Financial Highlights Revenue (Rs. Cr) Gross Profit (Rs. Cr) and Margin (%) 8.0% 8.3% 8.1% 9.0% 9.5% 5,096 486 +30% 3,922 +36% 352 3,300 2,522 268 210 1,780 142 FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 EBITDA (Rs. Cr) and Margin (%) Net Operating Working Capital (Days)* 1.2% 1.0%
Slide 33: Consolidated P&L Statement
Consolidated P&L Statement Particulars (Rs. Cr) FY25 FY24 FY23 FY22 FY21 Revenue 5,095.8 3,922.3 3,300.2 2,522.1 1,779.7 Cost of Goods Sold 4,609.5 3,570.4 3,031.9 2,312.4 1,638.1 Gross Profit 486.3 352.0 268.3 209.6 141.6 Gross Profit Margin 9.5% 9.0% 8.1% 8.3% 8.0% Employee Cost 195.5 149.4 128.1
Slide 34: Consolidated Balance Sheet
Consolidated Balance Sheet ASSETS (Rs. Cr) Mar-25 Mar-24 Mar-23 Mar-22 Mar-21 EQUITY AND LIABILITIES (Rs. Cr) Mar-25 Mar-24 Mar-23 Mar-22 Mar-21 ASSETS Equity Non-current assets Equity Share capital 43.5 43.5 4.1 3.9 0.1 Property, plant and equipment 57.0 41.0 43.2 45.7 40.9 Other equity 1,680.6 1,5
Slide 35: Consolidated Cash Flow Statement
Consolidated Cash Flow Statement Particulars (Rs. Cr) FY25 FY24 FY23 FY22 FY21 Net Profit Before Tax 138.7 35.6 -3.7 -19.8 -10.8 Adjustments for: Non Cash Items / Other Investment or Financial Items 44.0 86.6 -71.2 -41.5 42.7 Operating profit before working capital changes 182.8 122.2 67.5 21.7 31.8
Slide 36: Investor Relations Contacts
Company: Investor Relations Advisor: CIN: L74999HR2018PLC072204 CIN: U74140MH2010PTC204285 Mr. Nikhil Tibrewal Mr. Jigar Kavaiya / Parin Narichania E: irentero@ehspl.com E: jigar.kavaiya@sgapl.net / parin.n@sgapl.net T: +91-22-69019100 T: +91 9920602034 / +91 9930025733 www.enterohealthcare.com www.
Entero Healthcare Solutions — Q1 FY26 Earnings Presentation on 6ix